Do β2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?

被引：2
|
作者：
Chng, W. J. [1 ]
Jacobus, S. [2 ]
Fonseca, R. [1 ]
机构：
[1] Mayo Clin, Comprehens Canc Ctr, Scottsdale, AZ USA
[2] Dana Faber Canc Inst, Eastern Coop Oncol Grp Stat Ctr, Boston, MA USA
来源：
LEUKEMIA | 2008年 / 22卷 / 05期
关键词：
D O I：
10.1038/sj.leu.2405009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1080 / 1081
页数：3
相关论文
共 41 条
  • [1] Do β2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?
    W J Chng
    S Jacobus
    R Fonseca
    Leukemia, 2008, 22 : 1080 - 1081
  • [2] Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade)
    Kuglik, P.
    Zaoralova, R.
    Filkova, H.
    Greslikova, H.
    Nemec, P.
    Oltova, A.
    Pour, L.
    Adam, Z.
    Krejci, M.
    Hajek, R.
    CHROMOSOME RESEARCH, 2007, 15 : 185 - 186
  • [3] Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma
    Tian, Erming
    Epstein, Joshua
    Qu, Pingping
    Heuck, Christoph
    van Rhee, Frits
    Zangari, Maurizio
    Hoering, Antje
    Sawyer, Jeffery
    Barlogie, Bart
    Morgan, Gareth J.
    BLOOD, 2015, 126 (23)
  • [4] Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era
    Geng, Chuanying
    Yang, Guangzhong
    Zhou, Huixing
    Wang, Huijuan
    Li, Yanchen
    Leng, Yun
    Zhang, Zhiyao
    Jian, Yuan
    Chen, Wenming
    HEMATOLOGY, 2023, 28 (01)
  • [5] Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
    Reece, Donna
    Song, Kevin W.
    Fu, Tommy
    Roland, Birgitte
    Chang, Hong
    Horsman, Douglas E.
    Mansoor, Adnan
    Chen, Christine
    Masih-Khan, Esther
    Trieu, Young
    Bruyere, Helene
    Stewart, Douglas A.
    Bahlis, Nizar J.
    BLOOD, 2009, 114 (03) : 522 - 525
  • [6] Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and - 17p13 (p53) deletions in myeloma patients treated with high dose therapy
    Gertz, MA
    Lacy, MQ
    Dispenzieri, A
    Greipp, PR
    Litzow, MR
    Henderson, KJ
    Van Wier, SA
    Ahmann, GJ
    Fonseca, R
    BLOOD, 2004, 104 (11) : 99A - 99A
  • [7] Comparison of upfront transplantation strategies for newly diagnosed multiple myeloma with del(17p) and t(4;14)
    Gagelmann, N.
    Eikeema, D. -J.
    de Wreed, L.
    Koster, L.
    Rambaldi, A.
    Passweg, J.
    Garderet, L.
    Leleu, X.
    Kobbe, G.
    Schoenland, S.
    Yakoub-Agha, I
    Kroeger, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 98 - 98
  • [8] Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma
    Avet-Loiseau, H.
    Moreau, P.
    Mathiot, C.
    Charbonnel, C.
    Facon, T.
    Attai, M.
    Hulin, C.
    Marit, G.
    Minvielle, S.
    Harousseau, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting
    Garrido, David
    Slavutsky, Irma
    Riva, Eloisa
    CURRENT PROBLEMS IN CANCER, 2023, 47 (01)
  • [10] Location of the t(4;14) Translocation Breakpoint Identifies a Subset of Newly-Diagnosed Multiple Myeloma Patients with Poor Prognosis
    Stong, Nicholas
    Ortiz, Maria
    Towfic, Fadi
    Pierceall, William
    Flynt, Erin
    Thakurta, Anjan
    BLOOD, 2021, 138
12345